BioSpectrum Asia - August 2023Add to Favorites

BioSpectrum Asia - August 2023Add to Favorites

Obtén acceso ilimitado con Magzter ORO

Lea BioSpectrum Asia junto con 9,000 y otras revistas y periódicos con solo una suscripción   Ver catálogo

1 mes $9.99

1 año$99.99 $49.99

$4/mes

Guardar 50%
Hurry, Offer Ends in 12 Days
(OR)

Suscríbete solo a BioSpectrum Asia

1 año$11.88 $7.99

Holiday Deals - Guardar 33%
Hurry! Sale ends on January 4, 2025

comprar esta edición $0.99

Regalar BioSpectrum Asia

7-Day No Questions Asked Refund7-Day No Questions
Asked Refund Policy

 ⓘ

Digital Subscription.Instant Access.

Suscripción Digital
Acceso instantáneo

Verified Secure Payment

Seguro verificado
Pago

En este asunto

TAIWAN BIOMED INDUSTRY EYES $32B
Biomedicine is a top priority for Taiwan, with the government aiming to position the country as the leading hub for biomedical research and development in the Asia-Pacific region. By 2025, Taiwan aims to create 20 new medicines, introduce 80 high-value medical devices to the market, and elevate the biomedicine industry into a trillion-NT-dollar (approximately $32 billion) sector. The government has taken various initiatives, established biomedicines clusters and tweaked policies to achieve this goal. Has the effort paid off? How far has the country come to achieve its goals?

TAIWAN BIOMED INDUSTRY EYES $32B

Biomedicine is a top priority for Taiwan, with the government aiming to position the country as the leading hub for biomedical research and development in the Asia-Pacific region. By 2025, Taiwan aims to create 20 new medicines, introduce 80 high-value medical devices to the market, and elevate the biomedicine industry into a trillion-NT-dollar (approximately $32 billion) sector. The government has taken various initiatives, established biomedicines clusters and tweaked policies to achieve this goal. Has the effort paid off? How far has the country come to achieve its goals? Let's find out.

TAIWAN BIOMED INDUSTRY EYES $32B

10+ mins

Quality Concerns Hits APAC

India is not alone in witnessing adverse events of various drugs. Several countries such as Japan, China, Malaysia, Indonesia and many more have experienced challenges such as contamination, efficacy, and safety issues (with serious adverse events), resulting in drug recalls in the past few years. As with any incident, an in-depth look will bring forth the root of the problem. Let's explore.

Quality Concerns Hits APAC

4 mins

"The current challenge facing the life sciences R&D market is the sheer number of data generated and the ability to analyse"

A company previously affiliated with PerkinElmer, Inc., US-based Revvity, Inc was recently launched as an independent science-based solutions company that leverages innovation across life sciences and diagnostics to help improve lives everywhere.

"The current challenge facing the life sciences R&D market is the sheer number of data generated and the ability to analyse"

4 mins

Singapore Life Sciences Market: Salaries, Trends, and Expectations

With Singapore’s population projected to grow and age substantially by 2030, the government anticipates a significant increase in public health spending, reaching an estimated S$ 27 billion.

Singapore Life Sciences Market: Salaries, Trends, and Expectations

4 mins

BioSpectrum India honours Bio & Health Sciences stalwarts

Leaders from the Indian Bio & Health Sciences industry were felicitated by India’s leading Bio & Health Sciences publication, BioSpectrum for their outstanding contribution over the past two years.

BioSpectrum India honours Bio & Health Sciences stalwarts

2 mins

"India has huge talent in generics, chemistry, biology, developing novel vaccines but not in novel drug discovery"

“India has huge talent in areas such as generics, chemistry, biology, developing novel vaccines like mRNA, mDNA etc. but not in novel drug discovery” said Dr Anandkumar, Co-Founder & CEO, Bugworks Research.

"India has huge talent in generics, chemistry, biology, developing novel vaccines but not in novel drug discovery"

2 mins

Leer todas las historias de BioSpectrum Asia

BioSpectrum Asia Magazine Description:

EditorMM Activ Sci-Tech Communication

CategoríaBusiness

IdiomaEnglish

FrecuenciaMonthly

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.

  • cancel anytimeCancela en cualquier momento [ Mis compromisos ]
  • digital onlySolo digital